Eye implant for bleeding in diabetic retinopathy
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study tests an eye implant that continuously releases a medication called ranibizumab to treat bleeding in the eye caused by diabetic retinopathy. The implant may reduce the need for frequent eye injections and help maintain vision after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had bleeding in the eye from diabetic retinopathy and are scheduled for a type of eye surgery called pars plana vitrectomy.
- You have received at least two anti-VEGF injections (like ranibizumab, aflibercept, or bevacizumab) before the study starts.
- Your vision in the study eye is light perception or better.
- You are not pregnant, planning to become pregnant, or breastfeeding, and if you can get pregnant, you agree to use birth control during the study.
- You have not had certain prior eye surgeries or conditions, such as a retinal detachment repair, corneal transplant, or glaucoma surgery in the study eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an experimental eye drop can slow or treat early-stage diabetic retinopathy. If you have diabetes-related vision changes, this treatment might help prevent the condition from getting worse.
This trial tests if an injection of Vabysmo (faricimab) given before surgery can help people with eye bleeding from diabetic retinopathy. It aims to reduce blood in the eye and improve surgery outcomes.
This study follows patients with diabetic eye swelling (a complication of diabetes affecting the macula, the part of your eye needed for detailed vision) who are receiving anti-VEGF injections—a standard treatment that reduces abnormal blood vessel growth. Researchers will measure how well your retina (the light-sensitive tissue in your eye) recovers and functions over time.
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
Hear when a new Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.